Most patients undergoing mechanical ventilation (MV) in the intensive care unit (ICU) require sedation in order to tolerate the discomfort associated with the presence of an endotracheal tube, positive pressure ventilation or other invasive procedures. No sedative regimen has been found to be superior to all others.
Most patients undergoing mechanical ventilation (MV) in the intensive care unit (ICU) require sedation in order to tolerate the discomfort associated with the presence of an endotracheal tube, positive pressure ventilation or other invasive procedures. No sedative regimen has been found to be superior to all others.
All sedatives have side-effects, including drug accumulation, prolonged sedation, delirium and withdrawal syndromes. Potent short-acting agents such as propofol and dexmedetomidine have several advantages over longer-acting agents, which may include decreased MV times 1, 2 . Propofol and midazolam remain the two most commonly used sedative agents 3, 4 . Other interventions such as the use of a daily 'sedation break' and sedation scoresclinical tools for identifying the presence and severity of excessive sedation or delirium-have been advocated to reduce these side effects 5, 6 .
We sought to quantify the temporal changes in the duration of MV and the need for tracheostomy in our ICU, and the associated sedation management practices and the choice of intravenous sedative agent. We hypothesised that the combination of sedation score, sedation breaks and the preferential use of propofol over midazolam would be associated with a reduction in the duration of MV and need for tracheostomy.
MATERIALS AND METHODS
We undertook a retrospective eight-year observational analysis of MV adult patients in a 300-bed metropolitan teaching hospital with a ten-bed general medical/surgical ICU. Prospectively collected data were extracted from four independent databases: the hospital's administrative dataset 7 
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Patient care
The preferred sedative agents during MV in our ICU are midazolam and propofol, both administered by continuous intravenous infusion. These two drugs are rarely used for other indications in this ICU. For the purposes of this analysis we assumed all propofol and midazolam supplied to ICU was administered solely for the purpose of sedation of MV patients in the same year. The average infusion dose was calculated by dividing the total dose of drug supplied by the total number of MV hours during the same time period.
Morphine is used as an analgesic agent for both ventilated and non-ventilated patients. As we were unable to separate the supply of morphine to these two groups, data on morphine use was not analysed. Fentanyl by infusion was rarely used. Antipsychotic agent use in ventilated patients was difficult to quantify retrospectively, but total supply to ICU was small.
We defined long-term ventilation as MV duration >96 hours. The frequency of tracheostomy was extracted from the ICU procedural database and hospital coding data. Severity of illness was assessed using APACHE III-j 9 , SAPS 3 10 and the Critical Care Outcome Prediction Equation (version 3) 11 prediction models.
The Riker Agitation Sedation Score and 'sedation breaks' were gradually introduced into standard care from 2006 onwards. Daily compliance with sedation scoring and sedation break guidelines was assessed by weekly snapshot audits undertaken each year, using the number of MV days as the denominator.
Choice of sedation, use of tracheostomy, duration of MV and all other aspects of patient care were determined by the treating intensivist. There were no significant changes in ICU senior medical staffing and admission criteria, nor were there substantial changes in healthcare services in the hospital that might have affected case-mix or patient care.
Statistical analysis
Data are presented as the annual mean (standard deviation) or median (interquartile range), where appropriate. Temporal trends in continuous variables were assessed using negative binomial regression, where the measure (e.g. duration of MV) was the dependent variable, year of observation and predicted mortality the explanatory variables, and length-ofstay the exposure variable.
Trends in categorical variables (e.g. tracheostomy or death) were assessed using a logistic regression model where the measure of interest was the dependent variable and the year of observation and predicted mortality included as the explanatory variables. A P value <0.05 was used to designate statistical significance of trend data.
Data analysis was undertaken using Stata/MP version 11 software (StataCorp, College Station, Texas). Ethics approval was gained from the Northern Hospital Human Research Ethics Committee (LR 44/12). Consent was deemed unnecessary due to use of observational de-identified data.
RESULTS
Over the period 1 July 2002 to 30 June 2010, there were 5751 ICU admissions including 2102 (36.6%) who received MV (Figure 1) . A total of 395/2102 MV patients (18.8%) were classified as long-term and 369/2102 (15.2%) underwent a tracheostomy procedure. The demographic characteristics of the MV patients, and total midazolam and propofol supplied to ICU are presented in Table 1 .
Across the same time period there were substantial increases in annual ICU and MV admissions ( Table 1 and 2) without a significant change in gender, age or emergency admission rate. Annual data for tracheostomy, long-term ventilation and patient outcomes are displayed in Table 2 .
Over the eight-year period, there was a significant decrease in the supply and average estimated In temporal alignment there were substantial reductions in MV duration (P <0.001), tracheostomy rates (P=0.006), ICU length-of-stay (P <0.001) and hospital length-of-stay (P=0.005), without a change in illness severity scores (P=0.75; Table 1 ) ( Figure 3) .
The apparent decline in crude and risk-adjusted mortality did not reach statistical significance ( Table 2 ) using any of the three prediction models. APACHE III-j and SAPS 3 were found to overestimate risk substantially (as a result of historical and geographical factors 12 ) and the results using the Critical Care Outcome Prediction Equation model is reported herein.
The Riker Agitation Sedation Score sedation scoring system was introduced in 2005 and a daily 'sedation break' in 2006. The uptake and prevalence of the daily 'sedation break' was substantial, whereas the use of sedation scoring did not exceed 46% for the study period ( Table 3 ). The rate of decline in the duration of MV or lengthof-stay did not alter following the introduction of these interventions.
DISCUSSION
This retrospective observational analysis identified a marked fall in duration of MV, ICU lengthof-stay, hospital length-of-stay, the prevalence of long-term MV and the need for tracheostomy in ICU patients over an eight-year period. During this time there was a steady decline in the use of midazolam and rise in the use of propofol for sedation. The estimated average doses are within their therapeutic range. One plausible explanation for these findings is a causal link between the sedative regimen and the duration of therapy.
Our findings support other publications, suggesting that the use of propofol rather than midazolam may reduce the duration of long-term MV 2,13 and add additional evidence to suggest a decrease in both hospital and ICU length-of-stay. Drug characteristics may play a role in this. Both drugs are short-acting, easily titrated and equally effective in achieving sedation 2, [13] [14] [15] . The favourable pharmacokinetics of propofol-including shorter context sensitive half-time and lack of accumulation of active metabolites-might have contributed to the more rapid and predictable waking and time to extubation observed clinically [13] [14] [15] [16] [17] [18] . Whether sedative choice or pharmacokinetics have any influence upon ICU length-of-stay or whether institutional factors such as bed block are of more significance has been discussed in detail elsewhere 13, 17, 19 and are not specifically answered by this study. Propofol use in long-term infusion has been reported to have little overall impact on mortality 2 and the apparent fall in mortality in our study did not reach statistical significance (P=0.07). Several other plausible explanations for our findings also warrant consideration. These include the reverse hypothesis that therapeutic interventions (such as sedation scoring and sedation breaks) during the same period led to a reduction in MV duration and consequently a lower sedative consumption.
Targeting the level of sedation has been shown to reduce duration of MV and length-ofstay 20 . Mandatory daily sedation breaks have been shown to reduce both the duration of MV and length-of-stay, as well as the number of investigations for altered mental status, regardless of sedative agent used 5, 6 . These interventions are likely to have decreased the incidence of early deep sedation, which has been associated with increased time to extubation 21 .
The introduction of sedation scoring (Riker Agitation Sedation Score) and sedation breaks are likely to have led to earlier weaning and extubation. However, our observations do not support this hypothesis as the sole explanation. It would lead us to expect a decline in total sedative use and MV duration following the introduction of sedation scoring and daily 'sedation breaks'. It does not explain the decline in midazolam use and MV duration prior to, nor the rise in propofol dose after their introduction.
The prolonged observation period (of eight years) raises concern about subtle shifts in case-mix and severity that might also explain our findings. We were unable to identify any substantial change in case-mix based on admission diagnosis, patient demographics and severity of illness scores (Figure 3 ). Despite this we cannot exclude this as a potential source of unmeasured bias. Nor can we discount the limitation and methodological bias of an uncontrolled, retrospective and observational single-centre study. Other important sources of bias were not available for analysis, such as actual drugs and doses delivered, timing and indications for tracheostomy, weaning and extubation criteria. Although a causal link between sedative selection and MV duration cannot be proven, the outcomes of this study are consistent with the hypothesis that propofol is less likely than midazolam to result in prolonged sedation, thereby decreasing the duration of MV. Another short-acting sedative, dexmedetomidine, shows promise in reducing rates of delirium 1 and the outcomes of current trials are awaited. Future research should be aimed at characterising the interactions between sedative use and the implementation of strategies aimed at optimising sedation, analgesia and delirium control.
CONCLUSION
We identified a substantial fall in the duration of MV and ICU length-of-stay and rates of tracheostomy associated with the use of propofol in preference to midazolam as the primary sedative agent, over several years in a single centre. The available data suggest that the choice of sedative regimen appears to be a substantial factor. These findings have important clinical benefits for MV patients but require confirmation in a larger prospective multi-centre study.
